Cultures derived from pancreatic cancer xenografts with long-term gemcitabine treatment produce chemoresistant secondary xenografts: Establishment of isogenic gemcitabine-sensitive and -resistant models.

MLA

Kobayashi-Ooka, Yasuyo, et al. “Cultures Derived from Pancreatic Cancer Xenografts with Long-Term Gemcitabine Treatment Produce Chemoresistant Secondary Xenografts: Establishment of Isogenic Gemcitabine-Sensitive and -Resistant Models.” Pathology, Research and Practice, vol. 263, Nov. 2024, p. 155632. EBSCOhost, https://doi.org/10.1016/j.prp.2024.155632.

APA

Kobayashi-Ooka, Y., Akagi, T., Sukezane, T., Yanagita, E., Itoh, T., & Sasai, K. (2024). Cultures derived from pancreatic cancer xenografts with long-term gemcitabine treatment produce chemoresistant secondary xenografts: Establishment of isogenic gemcitabine-sensitive and -resistant models. Pathology, Research and Practice, 263, 155632. https://doi.org/10.1016/j.prp.2024.155632

Chicago

Kobayashi-Ooka, Yasuyo, Tsuyoshi Akagi, Taiko Sukezane, Emmy Yanagita, Tomoo Itoh, and Ken Sasai. 2024. “Cultures Derived from Pancreatic Cancer Xenografts with Long-Term Gemcitabine Treatment Produce Chemoresistant Secondary Xenografts: Establishment of Isogenic Gemcitabine-Sensitive and -Resistant Models.” Pathology, Research and Practice 263 (November): 155632. doi:10.1016/j.prp.2024.155632.